Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?

Kei Funaki, Shinichiro Nakajima, Yoshihiro Noda, Taisei Wake, Daisuke Ito, Bun Yamagata, Takahito Yoshizaki, Masashi Kameyama, Tadaki Nakahara, Koji Murakami, Masahiro Jinzaki, Masaru Mimura, Hajime Tabuchi

Research output: Contribution to journalArticle

Abstract

Background: Subjective cognitive decline (SCD) may herald the first symptoms of Alzheimer's disease (AD) whereas individuals with beta-amyloid (Aβ) deposition are regarded as a high-risk group for AD. Recently, amyloid positron emission tomography (PET) studies have demonstrated clinical and cognitive feature differences between Aβ-positive and negative SCD, but details of their differences remain unclear. We aimed to investigate the relationships among Aβ deposition, clinical, and cognitive features in patients with SCD. Methods: Forty-two patients with SCD (22 women, 74.5 ± 4.7 years) were examined using fluorine-18 florbetaben PET and were divided into Aβ-positive (n = 10) and negative (n = 32) groups. We compared cognitive and psychological outcomes, and single photon emission computed tomography (SPECT) imaging data between the two groups. In addition, a linear regression analysis was performed to assess relationships between the severity of SCD and neuropsychological tests, affective scores, and demographic factors. Results: The rate of score changes from the immediate recall to delayed recall in the logical memory subtest of the Wechsler's Memory Scale Revised were different between the groups (P = 0.04). However, the binary logistic regression analysis showed no significant differences between the two. In addition, the severity of SCD was significantly strong in women (P = 0.002). Furthermore, within the Aβ-negative group, subjective memory loss correlated with word fluency category score (P = 0.023) and apathy scale (P = 0.037). Conclusions: No significant differences were observed between Aβ-positive and -negative SCD on any of the neuropsychological measures, clinical measures, or SPECT imaging. Further, the severity of SCD was not predicted by the symptoms of anxiety, depression, or neuropsychological examination.

Original languageEnglish
JournalPsychogeriatrics
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Cerebrovascular Circulation
Regional Blood Flow
Amyloid
Cognition
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Alzheimer Disease
Regression Analysis
Wechsler Scales
Apathy
Fluorine
Cognitive Dysfunction
Neuropsychological Tests
Memory Disorders
Short-Term Memory
Linear Models
Anxiety
Logistic Models
Demography
Depression

Keywords

  • Alzheimer's disease
  • cognitive assessment
  • diagnosis and classification
  • memory clinics
  • positron emission tomography

ASJC Scopus subject areas

  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{892ff34b51774bc89bd300f939e214c6,
title = "Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?",
abstract = "Background: Subjective cognitive decline (SCD) may herald the first symptoms of Alzheimer's disease (AD) whereas individuals with beta-amyloid (Aβ) deposition are regarded as a high-risk group for AD. Recently, amyloid positron emission tomography (PET) studies have demonstrated clinical and cognitive feature differences between Aβ-positive and negative SCD, but details of their differences remain unclear. We aimed to investigate the relationships among Aβ deposition, clinical, and cognitive features in patients with SCD. Methods: Forty-two patients with SCD (22 women, 74.5 ± 4.7 years) were examined using fluorine-18 florbetaben PET and were divided into Aβ-positive (n = 10) and negative (n = 32) groups. We compared cognitive and psychological outcomes, and single photon emission computed tomography (SPECT) imaging data between the two groups. In addition, a linear regression analysis was performed to assess relationships between the severity of SCD and neuropsychological tests, affective scores, and demographic factors. Results: The rate of score changes from the immediate recall to delayed recall in the logical memory subtest of the Wechsler's Memory Scale Revised were different between the groups (P = 0.04). However, the binary logistic regression analysis showed no significant differences between the two. In addition, the severity of SCD was significantly strong in women (P = 0.002). Furthermore, within the Aβ-negative group, subjective memory loss correlated with word fluency category score (P = 0.023) and apathy scale (P = 0.037). Conclusions: No significant differences were observed between Aβ-positive and -negative SCD on any of the neuropsychological measures, clinical measures, or SPECT imaging. Further, the severity of SCD was not predicted by the symptoms of anxiety, depression, or neuropsychological examination.",
keywords = "Alzheimer's disease, cognitive assessment, diagnosis and classification, memory clinics, positron emission tomography",
author = "Kei Funaki and Shinichiro Nakajima and Yoshihiro Noda and Taisei Wake and Daisuke Ito and Bun Yamagata and Takahito Yoshizaki and Masashi Kameyama and Tadaki Nakahara and Koji Murakami and Masahiro Jinzaki and Masaru Mimura and Hajime Tabuchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/psyg.12397",
language = "English",
journal = "Psychogeriatrics",
issn = "1346-3500",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?

AU - Funaki, Kei

AU - Nakajima, Shinichiro

AU - Noda, Yoshihiro

AU - Wake, Taisei

AU - Ito, Daisuke

AU - Yamagata, Bun

AU - Yoshizaki, Takahito

AU - Kameyama, Masashi

AU - Nakahara, Tadaki

AU - Murakami, Koji

AU - Jinzaki, Masahiro

AU - Mimura, Masaru

AU - Tabuchi, Hajime

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Subjective cognitive decline (SCD) may herald the first symptoms of Alzheimer's disease (AD) whereas individuals with beta-amyloid (Aβ) deposition are regarded as a high-risk group for AD. Recently, amyloid positron emission tomography (PET) studies have demonstrated clinical and cognitive feature differences between Aβ-positive and negative SCD, but details of their differences remain unclear. We aimed to investigate the relationships among Aβ deposition, clinical, and cognitive features in patients with SCD. Methods: Forty-two patients with SCD (22 women, 74.5 ± 4.7 years) were examined using fluorine-18 florbetaben PET and were divided into Aβ-positive (n = 10) and negative (n = 32) groups. We compared cognitive and psychological outcomes, and single photon emission computed tomography (SPECT) imaging data between the two groups. In addition, a linear regression analysis was performed to assess relationships between the severity of SCD and neuropsychological tests, affective scores, and demographic factors. Results: The rate of score changes from the immediate recall to delayed recall in the logical memory subtest of the Wechsler's Memory Scale Revised were different between the groups (P = 0.04). However, the binary logistic regression analysis showed no significant differences between the two. In addition, the severity of SCD was significantly strong in women (P = 0.002). Furthermore, within the Aβ-negative group, subjective memory loss correlated with word fluency category score (P = 0.023) and apathy scale (P = 0.037). Conclusions: No significant differences were observed between Aβ-positive and -negative SCD on any of the neuropsychological measures, clinical measures, or SPECT imaging. Further, the severity of SCD was not predicted by the symptoms of anxiety, depression, or neuropsychological examination.

AB - Background: Subjective cognitive decline (SCD) may herald the first symptoms of Alzheimer's disease (AD) whereas individuals with beta-amyloid (Aβ) deposition are regarded as a high-risk group for AD. Recently, amyloid positron emission tomography (PET) studies have demonstrated clinical and cognitive feature differences between Aβ-positive and negative SCD, but details of their differences remain unclear. We aimed to investigate the relationships among Aβ deposition, clinical, and cognitive features in patients with SCD. Methods: Forty-two patients with SCD (22 women, 74.5 ± 4.7 years) were examined using fluorine-18 florbetaben PET and were divided into Aβ-positive (n = 10) and negative (n = 32) groups. We compared cognitive and psychological outcomes, and single photon emission computed tomography (SPECT) imaging data between the two groups. In addition, a linear regression analysis was performed to assess relationships between the severity of SCD and neuropsychological tests, affective scores, and demographic factors. Results: The rate of score changes from the immediate recall to delayed recall in the logical memory subtest of the Wechsler's Memory Scale Revised were different between the groups (P = 0.04). However, the binary logistic regression analysis showed no significant differences between the two. In addition, the severity of SCD was significantly strong in women (P = 0.002). Furthermore, within the Aβ-negative group, subjective memory loss correlated with word fluency category score (P = 0.023) and apathy scale (P = 0.037). Conclusions: No significant differences were observed between Aβ-positive and -negative SCD on any of the neuropsychological measures, clinical measures, or SPECT imaging. Further, the severity of SCD was not predicted by the symptoms of anxiety, depression, or neuropsychological examination.

KW - Alzheimer's disease

KW - cognitive assessment

KW - diagnosis and classification

KW - memory clinics

KW - positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85060673201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060673201&partnerID=8YFLogxK

U2 - 10.1111/psyg.12397

DO - 10.1111/psyg.12397

M3 - Article

AN - SCOPUS:85060673201

JO - Psychogeriatrics

JF - Psychogeriatrics

SN - 1346-3500

ER -